Tuesday, 02 January 2024 12:17 GMT
عربي


               US          Europe          Arab          Asia          Africa    
|      Politics          Economy     Oil&Energy         
                 Entertainment          Sport
Oncolytics Biotech Inc

Oncolytics Biotech Inc


2026-03-03 05:16:06
(MENAFN- Baystreet) 11:51 AM EST - Oncolytics Biotech Inc: Announced the initiation of a metastatic colorectal cancer Phase 2 study that will be referred to as REO 033. In this trial, second-line RAS-mutated, microsatellite-stable mCRC patients will be randomized to a control arm of bevacizumab (Avastin®) and fluorouracil, leucovorin, irinotecan or an experimental arm of pelareorep, bevacizumab, and FOLFIRI. The study is powered for statistical significance, with each study arm expected to enroll 30 patients. Oncolytics Biotech Inc shares N are trading -$0.08 at $1.04.

Full Press Release:

MENAFN03032026000212011056ID1110810528



Baystreet.ca

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Tags

Label

Comments

No comment

Category

Date
Search